ESR1 and breast cancer: We have previously shown that PER3 deletion is associated with tumor recurrence in patients with estrogen receptor (ER) positive breast cancers treated with tamoxifen, in addition, we also observed that low expression levels of PER3 may serve as a predictor of the probability of breast tumor recurrence in patients with ER-positive tumors11.